10mM in DMSO pour les flux de travail chromatographiques et analytiques sensibles nécessitant une interférence de ligne de base minimale.
Store at -80°C Expédition Dry ice packs + Cold packs. Consultez le COA spécifique au lot pour les spécifications exactes.
SDS, COA, fiche technique et fiche de spécifications disponibles au téléchargement. COA spécifique au lot accessible via la recherche par numéro de lot.
Cité dans 0 publications à comité de lecture couvrant la chromatographie, la synthèse organique et les réactions de couplage croisé.
SB 243213 is an orally active, selective and high-affinity 5-HT 2C receptor antagonist with a pK i of 9.37 and a pK b of 9.8 for human 5-HT 2C receptor. SB 243213 shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels. SB 243213 has improved anxiolytic profile and has the potential for schizophrenia and motor disorders
In Vitro
SB 243213 shows little affinity (pK i <6) for cloned human 5-HT 1A , 5-HT 1B , 5-HT 1E , 5- HT 1F and 5-HT 7 receptors. It shows weak affinity (pK i <6.5) for the cloned human 5-HT 1D and D3 receptors and moderate affinity (pK i =6.7) for the cloned human D2 receptor. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SB 243213 (0.1-10 mg/kg, p.o. 1 h pre-test) dose-dependently and significantly increases the amount of time rats spent in social interaction over 15 min under brightly lit conditions and in an unfamiliar test box . SB 243213 (0.3 mg/kg; p.o.; 1 h pre-test) significantly increases time spent in social interaction . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley experimentally naive rats (220-300 g) Dosage: 0.1, 0.3, 1, 3, 10 mg/kg Administration: PO; 1 hour pre-test Result: Dose-dependently and significantly increased the amount of time rats spent in social interaction over 15 min under brightly lit conditions and in an unfamiliar test box.
IC50& Target:Human 5-HT 2C Receptor 9.37 (pKi) human 5-HT 1A Receptor <5.3 (pKi) human 5-HT 1B Receptor 5.5 (pKi) human 5-HT 1D Receptor 6.32 (pKi) human 5-HT 1E Receptor <5.4 (pKi) human 5-HT 1F Receptor 5.35 (pKi) Human 5-HT 2A Receptor 7.01 (pKi) human 5-HT 2B Receptor 7.2 (pKi) Human 5-HT 6 Receptor 6.5 (pKi) Human 5-HT 7 Receptor 5.64 (pKi)
Document complet couvrant les dangers, la manipulation, le stockage et la conformité réglementaire.
<<<<<<< HEAD Télécharger la SDS → ======= Télécharger la SDS → >>>>>>> release248-p3Données qualité spécifiques au lot. Saisissez votre numéro de lot pour récupérer le COA exact.
Rechercher le COA →Résumé de référence rapide des spécifications et applications du produit.
Voir la fiche technique →Attributs de qualité complets et critères d'acceptation pour cette qualité.
Voir la fiche de spécifications →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
